Apollomics announces efficacy of vebreltinib in NSCLC patients

Apollomics announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress, ESMO, 2023, being held in Madrid, Spain from October 20-24, 2023. In the Phase 2 KUNPENG clinical trial conducted by Apollomics’ China partner, Avistone Biotechnology, vebreltinib showed efficacy in patients with locally advanced or metastatic NSCLC harboring Exon-14 skipping mutations, with an ORR of 75%. Among other notable findings in the KUNPENG study, ORR and disease control rate were 100% in patients with brain metastases and ORR was 66.7% in patients with liver metastases. Preliminary efficacy and safety data from the Phase 2 KUNPENG clinical trial is presented in poster 1378P. The data from NSCLC patients with MetEx14 skipping mutation showed the following efficacy results: Of the 52 patients, 39 achieved complete or partial response, an ORR of 75%, median duration of response of 15.9 months, a high disease control rate of 96.2%, and a notably rapid onset of response with a median time to response of 1 month. In the 35 treatment-naive patients, ORR was 77.1%, with median DOR of 16.5 months. In the 17 patients who received prior systemic treatment, ORR was 70.6%, with median DOR of 15.3 months.